BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 32881051)

  • 1. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
    Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
    Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor.
    Xu CB; Liu XS; Li JQ; Zhao X; Xin D; Yu D
    J Cell Biochem; 2019 Jun; 120(6):10830-10846. PubMed ID: 30706537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition.
    Zheng C; Quan RD; Wu CY; Hu J; Lin BY; Dong XB; Xia EJ; Bhandari A; Zhang XH; Wang OC
    J Cell Mol Med; 2019 Dec; 23(12):7974-7984. PubMed ID: 31568662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eva-1 homolog A promotes papillary thyroid cancer progression and epithelial-mesenchymal transition via the Hippo signalling pathway.
    Lin BY; Wen JL; Zheng C; Lin LZ; Chen CZ; Qu JM
    J Cell Mol Med; 2020 Nov; 24(22):13070-13080. PubMed ID: 32969138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHD4 Predicts Aggressiveness in PTC Patients and Promotes Cancer Stemness and EMT in PTC Cells.
    Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Alobaisi K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
    Jia M; Guo Y; Lu X
    Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells.
    Lee G; Kang YE; Oh C; Liu L; Jin Y; Lim MA; Won HR; Chang JW; Koo BS
    Auris Nasus Larynx; 2020 Oct; 47(5):870-880. PubMed ID: 32381353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing SIX1 inhibits epithelial mesenchymal transition through regulating TGF-β/Smad2/3 signaling pathway in papillary thyroid carcinoma.
    Min WP; Wei XF
    Auris Nasus Larynx; 2021 Jun; 48(3):487-495. PubMed ID: 33077306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial-mesenchymal transition.
    Zheng C; Xia EJ; Quan RD; Bhandari A; Wang OC; Hao RT
    Cell Biochem Funct; 2020 Mar; 38(2):158-166. PubMed ID: 31989658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3.
    You A; Fu L; Li Y; Li X; You B
    Cell Cycle; 2020 May; 19(10):1105-1121. PubMed ID: 32308106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
    Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
    J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wen J; Lin B; Lin L; Chen Y; Wang O
    Aging (Albany NY); 2020 Aug; 12(16):16437-16456. PubMed ID: 32857728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressed Krüppel‑like factor 17 expression induces tumor proliferation, metastasis and a poor prognosis in papillary thyroid carcinoma.
    Ye WC; Gao L; Huang J; Fang XM; Xie G
    Mol Med Rep; 2014 Oct; 10(4):2087-92. PubMed ID: 25109837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
    Pang R; Yang S
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.
    Luo D; Liu Y; Lin S; Tan L; Du Z; Long M; Zhu Y; Peng X; Zong W; Mackenzie GG; Li H; Ouyang N
    Oncol Rep; 2019 Feb; 41(2):1253-1263. PubMed ID: 30535496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA CASC2 expression is down- regulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway.
    Zhou T; Zhong M; Zhang S; Wang Z; Xie R; Xiong C; Lv Y; Chen W; Yu J
    Cancer Biomark; 2018; 23(2):185-191. PubMed ID: 30175973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of miR-421 predicts poor prognosis and promotes proliferation, migration, and invasion of papillary thyroid cancer cells.
    Dong A; Zhang J; Sun W; Hua H; Sun Y
    J Chin Med Assoc; 2020 Nov; 83(11):991-996. PubMed ID: 32881717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between activated STAT3 protein and epithelial-mesenchymal transition in papillary thyroid carcinoma].
    Zhang Z; Bai Y; Li P; Zhao J; Wang Y; Sun L; Tang J
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Nov; 27(22):1265-8. PubMed ID: 24616987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulating integrin subunit alpha 7 (ITGA7) promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition.
    Guan Y; Bhandari A; Xia E; Kong L; Zhang X; Wang O
    Acta Biochim Biophys Sin (Shanghai); 2020 Feb; 52(2):116-124. PubMed ID: 31942970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of RET gene mediated EGFR signaling pathway on epithelial-mesenchymal transition, proliferation and apoptosis of papillary thyroid carcinoma cells.
    Zhao YL; Yuan BQ; Shen GS
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8036-8047. PubMed ID: 32767330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.